St. Jude Children’s Research Hospital has the first and only National Cancer Institute-designated St. Jude Comprehensive Cancer Center devoted solely to children. St. Jude freely shares research and clinical discoveries to ensure doctors and scientists worldwide have the necessary knowledge to help save more children.
To schedule an interview with an expert, email media@stjude.org.
Pediatric Cancer Experts
-
James R. Downing, MD
Downing
James Downing, MD, is President and Chief Executive Officer at St. Jude Children's Research Hospital, as well as the hospital’s chair of Childhood Cancer Treatment. Downing was instrumental in launching the Pediatric Cancer Genome Project and was a finalist of TIME magazine's 100 most influential people in the world.
-
Elizabeth Fox, MD, senior vice president, clinical trials research and associate director for clinical research in the St. Jude Comprehensive Cancer Center, oversees clinical trials research administration and strategy. She is an expert in the integration of clinical and pre-clinical pharmacology in clinical trials designed for childhood cancer.
-
Ellis J. Neufeld, MD, PhD
Neufeld
Ellis Neufeld, MD, PhD, St. Jude executive vice president, clinical director and physician-in-chief, oversees the organization's academic clinical departments and all clinical operations. He is an experienced clinical and translational investigator and an internationally respected pediatric hematology leader.
-
Kim E. Nichols, MD
Nichols
Kim Nichols, MD, St. Jude Department of Oncology, Division of Cancer Predisposition director, studies the molecular mechanisms that protect against viral infections and cancer to learn how defects in these mechanisms contribute to disease. She uses this information to develop more effective treatments for children with increased genetic risk for infection or malignancy.
-
Julie Park, MD
Park
Julie Park, MD, St. Jude Department of Oncology chair, has a strong track record translating laboratory research findings into early-phase clinical trials for recurrent childhood malignancies. In particular, she collaborated with laboratory investigators in designing the first in-human autologous chimeric antigen receptor (CAR) T-cell trials for pediatric leukemia, solid tumors and brain tumors. Park has also developed novel combinatorial therapies for particularly difficult-to-treat neuroblastomas.
-
Charles W. M. Roberts, MD, PhD
Roberts
Executive Vice President Charles Roberts, MD, PhD, St. Jude Comprehensive Cancer Center director, leads research in the field of cancer epigenetics. Roberts’ work has led to new investigational cancer therapies for both children and adults, studying how chromatin remodeling complexes, which normally allow access to DNA so genes can be transcribed, contribute to cancer.
-
Carlos Rodriguez-Galindo, MD
Rodriguez-Galindo
Executive Vice President Carlos Rodriguez-Galindo, MD, St. Jude Department of Global Pediatric Medicine chair and St. Jude Global director, is a world-recognized leader in global childhood cancer care. Rodriguez-Galindo is instrumental in efforts to improve both the access to and quality of care children receive in low- and middle-income countries.
